MRNA technology takes on autoimmune diseases in early trial
NCT ID NCT07388212
First seen Feb 05, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This early-phase study tests a new mRNA drug that targets and clears faulty immune cells (B cells and plasma cells) in people with relapsed autoimmune diseases. The goal is to reset the immune system and reduce symptoms. About 27 adults aged 18-70 will receive the treatment to check safety and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.